What peer-reviewed clinical trials evaluated Neurocept treatments for PTSD by 2024?
Executive summary
Available 2024–2025 systematic and regulatory summaries document multiple clinical trials of novel PTSD treatments in Phase II and Phase III, but the provided search results do not name any peer‑reviewed clinical trials conducted by or labeled “Neurocept” for PTSD through 2024; available sources either do not mention Neurocept or focus on other sponsors and investigational agents (not found in current reporting) [1] [2] [3].
1. What you asked and what the sources show
You asked which peer‑reviewed clinical trials evaluated Neurocept treatments for PTSD by 2024. The documents in the supplied results describe many PTSD trials, pipeline drugs, and agency reviews — including Phase II and Phase III research summarized by ICER and by a June‑1, 2024 pipeline review — but none of the cited materials mention Neurocept by name or list Neurocept‑sponsored peer‑reviewed PTSD trials (not found in current reporting) [1] [2] [3].
2. Large, late‑stage PTSD programs documented in 2024
Independent reviewers and systematic overviews cited in the search results report multiple Phase II and Phase III PTSD trials generally: ICER’s 2024 PTSD draft report references “thirteen Phase II and two Phase III trials” in its analyses and discusses MDMA‑assisted therapy as an example that reached late‑stage review by regulators [1]. A systematic review of psychiatric pipelines counted five agents in Phase III for PTSD as of June 1, 2024 [2] [3].
3. The high‑profile case many reports focus on: MDMA and regulatory pushback
News coverage and policy summaries in the results highlight the MDMA‑assisted therapy program that reached Phase III and regulatory scrutiny in 2024: the FDA advisory committee voted against approval in June 2024 and the agency later requested more data from the sponsoring company, prompting reporting that approval was declined in August 2024 [4]. These items illustrate how a prominent late‑stage PTSD program can dominate summary reports and reviews even while many other trials proceed [1] [4].
4. Why “Neurocept” might not appear in these summaries
The pipeline and repository documents pulled together broad inventories of trials and sponsors; many university and center trial listings (UCSF, UCSD, UCLA) in the results show investigator‑initiated RCTs and device or behavioral studies rather than industry programs tied to a specific commercial name [5] [6] [7]. The specific absence of Neurocept in these sources may reflect that Neurocept either did not sponsor peer‑reviewed PTSD trials reported in these public summaries by 2024 or that any Neurocept trials exist but are not mentioned in these particular documents (not found in current reporting) [5] [1] [2].
5. Limits of the current evidence and reporting bias to note
The available sources are comprehensive in scope but not exhaustive: ICER and pipeline reviews aggregate many trials but may emphasize higher‑profile industry programs and late‑stage candidates [1] [2]. Clinical trial registries or later peer‑reviewed papers might record smaller or earlier Neurocept studies that these summaries omitted; however, the documents you provided do not cite any Neurocept peer‑reviewed PTSD trials (not found in current reporting) [1] [3].
6. How to confirm whether Neurocept ran peer‑reviewed PTSD trials
To resolve the gap the current materials reveal, consult primary sources not in the supplied set: PubMed/PMC for peer‑reviewed publications, ClinicalTrials.gov for registered Neurocept studies, and company filings or press releases from Neurocept (available sources do not mention these steps directly) [8]. The supplied ICER and pipeline syntheses demonstrate the kinds of reports that would note late‑stage, peer‑reviewed results when present [1] [2].
7. Bottom line for readers and researchers
Based on the supplied search results, there is documented late‑stage clinical activity for several PTSD candidates through 2024, but none of the cited sources identify peer‑reviewed clinical trials of “Neurocept” treatments for PTSD. That absence is not proof such trials never happened — it is a gap in these particular sources; verifying Neurocept’s trial record requires checking registries, company disclosures, and the peer‑review literature directly (not found in current reporting) [1] [2] [3].